Search PubMed⌕ Search

Biomedical subjects

G Montanari

Publications and source records attributed to G Montanari.

At least 109 records · Page 6Linked to original sources
PubMed1985

Absorption and disposition kinetics of flunoxaprofen and benoxaprofen in healthy volunteers.

Flunoxaprofen is a new nonsteroidal antiinflammatory agent that, like benoxaprofen, inhibits leukotriene rather than prostaglandin synthesis. The absorption and disposition kinetics of flunoxaprofen and benoxaprofen have been compared in six healthy volunteers after oral administration of 100 mg of each drug. The two drugs showed similar absorption characteristics, whereas the distribution and elimination processes were much faster for flunoxaprofen. The renal route of elimination appeared to contribute significantly less to the disposition of flunoxaprofen. These kinetic characteristics render less likely the risk of excessive drug accumulation with flunoxaprofen, especially in the presence of reduced renal function.

Adult↗
PubMed1985

Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.

Procetofen, a new hypolipidemic drug with a powerful cholesterol and triglyceride lowering activity, was administered to hypertriglyceridemic patients, in an effort to determine the major lipoprotein and apoprotein changes, thus providing an insight of the drug's mechanism of action. The twenty-six selected patients (13 type IIB and 13 type IV) were given 100 mg tid of the compound for 9 weeks. Procetofen lowered triglycerides in plasma (-50%) and in all lipoprotein classes (-30-50%) in both patient groups; an 18% reduction of low density lipoprotein cholesterol levels also occurred in type IIB patients. High density lipoprotein cholesterol generally increased significantly, with a maximum of 11% in type IV patients. Plasma apolipoproteins showed a pattern of changes, characteristic of each hyperlipoproteinemia phenotype, reversible after the end of drug treatment. Apoprotein B decreased 16% in type IIB patients, but was not modified in type IV. Conversely, apoprotein CII increased significantly in the very low density lipoproteins of both groups of treated subjects, with a reduction of CIII-1. These findings support the hypothesis that procetofen may act primarily as a stimulator of the catabolism of triglyceride rich lipoproteins. On the other hand, the significant reduction of total and low density lipoprotein cholesterol levels in type IIB, also indicates that other mechanisms, possibly related to changes in the direct liver secretion of apoprotein B or to remnant removal, may be operative with this new drug.

Adult↗
PubMed1984

Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia.

Pantethine (P), the stable disulphate form of pantetheine, major component and precursor of coenzyme A, was evaluated within a double-blind protocol (8 weeks for P or for a corresponding placebo) in 29 patients, 11 with type IIB hyperlipoproteinemia, 15 with type IV, and 3 with an isolated reduction of high density lipoprotein cholesterol (HDL-C) levels. In type IIB patients, P (300 mg t.i.d.) determined a highly significant lowering of plasma total and low density lipoprotein (LDL) associated cholesterol (-13.5% for both parameters). In the same patients, HDL-C levels increased about 10% at the end of treatment. Switching from P to placebo was associated with a rapid return to the baseline cholesterolemia. Both in type IIB and type IV patients, plasma triglyceride levels were reduced around 30%, when P was given as the first treatment; when it was preceded by placebo, reductions were less striking (respectively, -17.8% for type IIB and -13.0% for type IV, at the end of P treatment). HDL-C levels were not increased by P, either in type IV, and in the patients with low HDL cholesterolemia. In type IV, LDL cholesterol levels showed a variable response to P: they tended to increase when below 132 mg/dl, prior to treatment, and to be reduced when above this level. This study provides evidence for a significant hypocholesterolemic effect of P, a natural compound free of overt side effects. It also indicates that P may raise HDL-C levels in type IIB patients, while moderately reducing triglyceridemia.

Adult↗
PubMed1983

Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.

Changes in plasma lipoprotein levels and platelet reactivity were evaluated during sequential treatments with clofibrate and tiadenol, two hypolipidemic agents with apparently different mechanisms, in 27 hyperlipoproteinemic patients. The objective of the study was to determine the pattern of plasma lipoprotein variations, induced by a drug mainly affecting lipoprotein catabolism (clofibrate) and by a drug affecting biosynthesis (tiadenol), and to single out-patients specifically responding to either treatment. Both drugs proved significantly active in type IIA and IV hyperlipoproteinemias, not in type IIB. Clofibrate significantly lowered very low density lipoprotein (VLDL) associated cholesterol in all three hyperlipoproteinemia phenotypes, and it also lowered VLDL triglycerides in type IV, while increasing high density lipoprotein (HDL) cholesterol in type IIA patients. Low density lipoprotein (LDL) cholesterol levels were minimally reduced by clofibrate in type IIA (-4%), and increased in types IIB (+ 14.2%) and IV (+ 6.1%) patients. Conversely, tiadenol lowered VLDL cholesterol and triglycerides to a lesser extent, but it did significantly reduce LDL cholesterolemia in type IIA (-17.6%), while increasing HDL cholesterol in type IIB. Statistical evaluation of the results did not permit identification of parameters associated with the response to either drug, although individuals specifically responding to one or the other agent, or to both, were detected in all three phenotypes. The sensitivity to the major platelet aggregating factors, ADP, adrenaline and collagen, was not significantly altered after drug treatments. Evaluation of the hypolipidemic response to agents with different mechanisms may be of help in selecting the best treatment for individual patients.

Adult↗
PubMed1983

Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study.

62 patients with histologically confirmed sarcoidosis (7 with Stage 0, 9 with Stage I, 20 with Stage II, 26 with Stage III) underwent right heart haemodynamics (Swan Ganz) and M-mode echocardiography. Haemodynamic study showed mild to moderate pulmonary hypertension in many patients with Stage II and III sarcoidosis, and 5 patients with Stage 0 healed sarcoidosis, showed borderline values of right sided pressures. Echocardiographic study showed increased right ventricular index (RVI) and right ventricular anterior wall thickness (RVAWT) in most patients. The good correlations between echocardiographic and haemodynamic data suggest that echocardiography may be a useful technique for the non-invasive assessment of the effects of pulmonary hypertension on the right heart in sarcoidosis.

Adult↗
PubMed1983

Atypical indications for Ender's osteosynthesis.

On the basis of a considerable experience in the use of Ender's nails in basal and trochanteric fractures of the neck of the femur, the authors are convinced of the excellent mechanical properties of this fixation device. They have therefore used it in five atypical and complex cases of subtrochanteric fracture. They describe and discuss the clinical and radiological results obtained. Their reasons for choosing this method in preference to rigid osteosynthesis are given in each case.

Adolescent↗
PubMed1983

Tolerability and serum levels of benoxaprofen in healthy volunteers.

Tolerability, serum levels and urinary excretion of benoxaprofen (B) in therapeutic doses of 400 or 600 mg as a capsule were studied in 22 healthy volunteers after single or multiple doses. B was determined by a HPLC procedure. Apart from a skin reaction in one patient, no major problems were encountered by patients. Mean serum peak values after 400 and 600 mg were 49.84 and 94.54 micrograms/ml respectively. Mean time to peak was 5.6 hours and mean half-life ranged between 45.38 (400 mg regimen) and 63.48 hours (600 mg regimen). Urinary excretion was only a fraction of the doses ingested: 14.39% after a single dose; 35.5% after multiple doses. This may depend on other pathways of elimination of the drug because steady state is reached according to half-life.

Adult↗
PubMed1982

Plasma lipid and lipoprotein changes in hypertensive patients treated with propranolol and prazosin.

The effects of propranolol and prazosin on plasma lipoproteins in patients with essential hypertension were evaluated according to a crossover protocol of two 8-week periods with a washout of 4 to 6 weeks. Eleven patients with moderate hypertension (greater than 90 but less than or equal to 144 mm Hg, diastolic) and slightly overweight (+10% to +/- +30%, according to Metropolitan Life Insurance tables) were selected. No dietary changes were prescribed. Plasma cholesterol, triglycerides (TG), and lipoprotein changes were monitored at the beginning of each sequence and at 2-, 4- and 8-week intervals. Prazosin, when given first, did not essentially modify any of the metabolic parameters, except for a slight elevation in plasma apoprotein AI levels, i.e., the main protein component of high density lipoprotein (HDL); propranolol caused a significant rise in total TG and very low density lipoprotein TG (VLDL-TG) levels (+37.3% and +23.9%, respectively). Somewhat lower total TG (+19.6%) and vLDL (17.8%) TG elevations were noted when propranolol was given first; plasma glucose was also significantly raised (+12.8%). Triglyceride and glucose levels returned to normal upon changing to prazosin. Total plasma- and lipoprotein-associated cholesterol levels were essentially unchanged with either drug; similarly, no significant changes were detected in total plasma apoprotein B (the main protein component of LDL and also VLDL), a component of apoprotein AI levels. Uric acid levels were slightly raised on propranolol. There was an 8.8% reduction in uric acid levels when the medication changed from propranolol to prazosin.

Apoproteins↗
PubMed1981

[The evaluation of dental pulp circulation using photoplethysmography].

Photoplethysmography is a technique for investigating changes in tissue opacity. Applied on human teeth it demonstrated the changes occurring in dental pulp circulation during different conditions as deep inspiration, Valsalva maneuver, cooling and compression. It is suggested that the photoplethysmography can be used as a vitality test for human teeth especially after recent traumas and orthodontic treatments.

Dental Pulp↗
PubMed1981

[Oropharyngeal lymphoid tissue as a bursa-equivalent structure: embryological and clinical considerations].

If we examine with an ontogenetic viewpoint the tissues giving origin to both thymus and avian bursa of Fabricius, we can't ignore that they are primary lymphoid organs connected to areas of ecto-entodermic junctions. They have a strong development in the embryonic life while tending to regress in the adult. The analysis of the organogenesis clarifies this affirmation. In the human cephalic district we know of various ectoentodermic stratification areas: the branchial pockets and the Remake pharyngeal membrane. The oral-pharyngeal lymphoid tissue is histogenetically linked to the stem-cells of the marrow which migrate to occupy an initially ecto-entodermic milieu. Structural and ontogenetic analogies of embryological nature lead to an identification of the oral-pharyngeal lymphoid tissue in man with the avian bursa of Fabricius. Therefore we deem it very indicative that a humoral immunological deficiency syndrome appears in subjects with the atrophy of the Waldeyer ring; above all considering that an experimental model of the humoral immunological deficit has been reproduced in chicken surgically or hormonally bursectomized.

Animals↗